Infinity Pharma (INFI) Tops Q3 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall St set for higher open as Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
- AMD gets bullish pre-earnings call from Lynx as server CPU demand accelerates
- Array Technologies and Shoals Technologies agree to stock-for-stock merger
- Marathon Petroleum to sell two refineries to CVR Energy for $4.2B
- AMD forecast eases AI spending fears as data-center sales surge
- Moderna shares rise ahead of Thursday earnings report
- After-Hours Movers: AMD, SMCI, SWKS, NRIX, TOST, BKNG
- After-Hours Movers: AMZN, TWLO, INTC, SNDK, RDDT, RBLX, PINS, RIVN, SBUX, ILMN
- After-Hours Movers: GOOGL, MSFT, NOW, KLAC. CMG, CVNA, TDOC
- After-Hours Movers: STX, ENPH, HOOD, V, CSGP, BOOM, CAKE, PPG, OI, TER
- After-Hours Movers: CLS, AVGO, CDNS, AMKR, WHR
Infinity Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Company Update
November 2, 2021 4:05 PM EDTEncouraging data for eganelisib in both PD-L1(-) and PD-L1(+) mTNBC patients, with meaningful prolongation of PFS over IMpassion130 reference benchmark
Updated mTNBC data to be presented at San Antonio Breast Cancer Symposium
Encouraging data for eganelisib in mUC patients, with a 7.5 month extension of overall survival versus control arm
Strengthened leadership team with Chief Scientific Officer, Chief Medical Officer and Board appointments
CAMBRIDGE, Mass.--(BUSINESS... More



